When Colonization Is Not the Culprit: Multidrug‐Resistant Gram‐Negative Urinary Tract Infections as a Marker of Risk After Kidney Transplantation

In this issue, Palmisano et al. [1] address a question of immediate clinical importance in kidney transplantation: whether multidrug-resistant (MDR) Gram-negative urinary tract infection (UTI) is simply a marker of clinical complexity or a distinct determinant of inferior graft and immunologic outcomes. In this retrospective, single-center cohort study, 521 kidney transplant recipients were followed for 24 months. At specified points, patient events were recorded that stratified transplant recipients into the following categories: MDR Gram-negative infection, presumptive MDR infection (without microbiologic confirmation), and non-MDR infection. The authors found that MDR Gram-negative infection, presumptive MDR infection, and non-MDR Gram-negative infection were independently associated with acute rejection, CMV viremia, and/or reduced graft survival. The principal value of this study lies in its disentangling of microbiologic states that are often conflated in clinical practice. MDR colonization was common, occurring in 212 of 521 recipients (40.7%), whereas documented MDR infection occurred in 92 (17.7%). Importantly, only documented MDR infection retained an independent association with clinically consequential endpoints. Statistically significant reduction in graft survival related to MDR infection is a focal difference between this study and previously published reports [2]. This distinction has direct implications for how clinicians manage resistant organism detection after transplantation, an often-arduous clinical task. Furthermore, the study improves upon prior work [3] by modeling infectious states as time-varying and overlapping rather than static and mutually exclusive events. The authors' modeling choice more accurately reflects the realities of clinical practice, in which patients move between colonization and infection over time and may experience repeated or sequential infectious episodes. The association with CMV viremia is particularly noteworthy. As presented, this observation suggests that MDR infection may mark deeper net immunosuppression, a higher burden of invasive devices or procedures, or broader disruption of host–pathogen equilibrium. Even if causality cannot be inferred, the association with biopsy-proven rejection reinforces the complicated relationship between infection, immune modulation, and alloimmune risk, arguing against MDR UTI being a narrow microbiologic problem. Several limitations deserve mention. This was a retrospective, single-center study conducted in a high-endemic setting, and its screening protocols, antimicrobial practices, and clinical thresholds may not be directly generalizable to all transplant programs. The “presumptive MDR” category is especially vulnerable to misclassification because it relies on clinician judgment without microbiologic confirmation. Even with these caveats, the clinical implications from Palmisano et al. are compelling and impact transplant practitioners broadly. Documented MDR Gram-negative UTI after kidney transplantation appears to identify patients at substantially increased risk for downstream virologic, immunologic, and graft-related complications, whereas colonization alone does not appear to carry the same prognostic weight. These findings help inform future efforts to align antimicrobial stewardship and posttransplant surveillance with individualized risk. It also highlights the need for further research, including a multicenter study that would allow for more generalizable outcomes, alleviating the aforementioned single-center limitations. A possible prospective study would also increase the depth of the MDR UTI literature and allow for extended time-period analysis beyond the 24 months in this current study.